Aug 2026
SGLT2i Canagliflozin Exerts Neuroprotection in Diabetic Retinopathy by Inhibiting Microglial Proinflammatory Cytokine Release by Downregulating the TLR4/NF-κB/NLRP3 Pathway.
These findings identify CANA as a promising therapeutic candidate for DR, acting through TLR4/NF-κB/NLRP3-dependent modulation of microglial activation and inhibited the TLR4/NF-κB/NLRP3 pathway.
Tai Guo, Yue Liu, Mengxiao He et al.
· Current Eye Research · 0 citations